Guidelines for Patients Details
Dynamic landing page for Patient Guidelines
Dynamic landing page for Patient Guidelines
Retreatment with daratumumab-based regimens led to a similar ORR vs initial daratumumab treatment in relapsed/refractory myeloma.
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses the findings of the observational GIMEMA CLL2121 study (NCT04867915),…
Trastuzumab deruxtecan improved responses and survival vs T-DM1 in HER2+ metastatic breast cancer after prior exposure to trastuzumab and a taxane.
ASTRO holds annual elections for its Board of Directors.
ASTRO holds annual elections for its Board of Directors.
Getting rid of the disease and infection is just as important as eliminating the stigma surrounding the disease.
Apalutamide/ADT maintains quality of life, demonstrates improved PSA progression-free survival in recurrent prostate cancer according to PRESTO trial.
Teclistamab plus daratumumab and lenalidomide had a manageable safety profile in patients with transplant-ineligible, newly diagnosed multiple myeloma.
Eunice S. Wang, MD, discusses current unmet needs and efforts to move menin inhibitors into earlier lines of therapy in relapsed/refractory AML.
The combination of RP1 and nivolumab was safe and effective in patients with anti–PD-1-failed advanced melanoma.